Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Schiff, R"'
Publikováno v:
The Breast. 24:S60-S66
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although endocrine therapy targeting ER is highly effective, intrinsic or acquired resistance is common, significantly jeopardizing treatment outcomes and mini
Autor:
Sabrina Herrera, Meghana V. Trivedi, Sufeng Mao, Mario Giuliano, Joe W. Gray, Carmine De Angelis, Sara López-Tarruella, Huizhong Hu, Laura M. Heiser, Yen-Chao Wang, C. Kent Osborne, Rachel Schiff, Nicholas J. Wang, Mothaffar F. Rimawi, Anne Pavlick, Agostina Nardone, Jenny C. Chang, Alejandro Contreras, Susan G. Hilsenbeck, Gary C. Chamness, Xiaoyong Fu, Tao Wang, Carolina Gutierrez
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose: To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor (ER) and Bcl2 in preclinical models and clinical tumor samples. Experimental desi
Publikováno v:
Nature Reviews Clinical Oncology. 12:573-583
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, treated with endocrine therapies. However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventu
Autor:
C. Kent Osborne, Carmine De Angelis, Jorge S. Reis-Filho, Jamunarani Veeraraghavan, Aleix Prat, Mothaffar F. Rimawi, Rachel Schiff, Tomás Pascual
Overexpression and/or gene amplification of HER2, a crucial member of the HER family of four receptors, occur in about 15-20% of breast cancers and define an aggressive subtype of the disease. Activated HER homo and heterodimers govern a complex and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91fc5b38c62a2a02712292d649c32db7
https://europepmc.org/articles/PMC6050048/
https://europepmc.org/articles/PMC6050048/
Autor:
Sabino De Placido, Richard M Elledge, Rachel Schiff, Heidi L. Weiss, Grazia Arpino, C. Kent Osborne, Adrian V. Lee
Publikováno v:
Journal of the National Cancer Institute. 97(17)
Background: Clinical data indicate that estrogen receptor – positive/progesterone receptor – negative (ER + /PR − ) breast cancers are less sensitive to tamoxifen than are ER + /PR + tumors. It has also been reported that tamoxifen may be less